Sarah Kim

Sarah Kim, Ph.D.

Research Assistant Professor

Department: Pharmaceutics
Business Phone: (407) 313-7044
Business Email:

About Sarah Kim

Sarah Kim, Ph.D. is a Research Assistant Professor in the Department of Pharmaceutics at the University of Florida. She is a practicing pharmacometrician with a background in Applied Mathematics. As an early-stage Principal Investigator, she is leading several funded computational modeling projects to create and innovate quantitative solutions in healthcare. The shared goal of these proejcts is to develop model-based clinical trial simulation tools, which will help drug developers optimize clinical trial designs.

She graduated summa cum laude with the President’s honor with a Bachelor’s degree in 2008, and completed her Master’s degree in 2010 both in Applied Mathematics from Hanyang University, South Korea. She earned her doctorate in Biomathematics at Florida State University in 2015. She has received several awards including David Goldstein and Presidential Trainee Awards from the American Society for Clinical Pharmacology and Therapeutics.


Peer Review Award for Pharmacology & Toxicology
2018 · Publons
Presidential Trainee Award
2018 · American Society for Clinical Pharmacology and Therapeutics
David Goldstein Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Presidential Trainee Award
2017 · American Society for Clinical Pharmacology and Therapeutics
Landahl Travel Grant
2015 · Society of Mathematical Biology
2012-2013 · Southern Scholarship Foundation
Pi Mu Epsilon Honor
2012 · National Pi Mu Epsilon Council
Poster Presentation Award
2009 · Korean Society for Mathematical Biology
Graduate Research Fellowship
2008-2010 · LG Corporation Yonam Foundation
Summa Cum Laude Graduation Honors
2008 · Hanyang University
Volunteer Corps Essay Contest Award
2007 · Hanyang University
2006-2007 · Beakwoon Scholarship Foundation
Full Tuition Scholarship
2004-2007 · Hanyang University

Research Profile

Dr. Kim’s current research focuses on:

(1) Mathematical modeling and simulation informing experimental designs to examine combinations of anti-Mycobacterium tuberculosis agents to identify optimal regimens which markedly shorten the length of tuberculosis treatments and prevent the emergence of resistance.

(2) Developing disease progression model-based clinical trial simulation tools to optimize clinical trial enrichment and design of studies to investigate the efficacy of potential therapies for Duchenne muscular dystrophy and type 1 diabetes.

In addition, she envisions developing Artificial Intelligence (AI)-assisted imaging analysis and informatics tools that will accelerate the analysis of imaging data and provide insights into better understanding of disease progression. Ultimately, the AI-based tools will help in the rational design of disease prevention and treatment strategies.


Dose-fractionation of moxifloxacin for the treatment of tuberculosis: impact of dosing interval and elimination half-life on microbial kill and resistance suppression.
Antimicrobial agents and chemotherapy. [DOI] 10.1128/AAC.02533-20. [PMID] 33468465.
In Vitro Synergistic Interactions of Isavuconazole and Echinocandins against Candida auris
Antibiotics. 10(4) [DOI] 10.3390/antibiotics10040355.
Physiologically Based Pharmacokinetics Modeling to Investigate Formulation Factors Influencing the Generic Substitution of Dabigatran Etexilate.
CPT: pharmacometrics & systems pharmacology. [DOI] 10.1002/psp4.12589. [PMID] 33449439.
The Funnel: a Screening Technique for Identifying Optimal Two-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy. 65(2) [DOI] 10.1128/AAC.02172-20. [PMID] 33199386.
Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically-based modeling as a candle in the dark.
British journal of clinical pharmacology. 86(11):2247-2255 [DOI] 10.1111/bcp.14326. [PMID] 32335930.
Building Optimal Three-Drug Combination Chemotherapy Regimens.
Antimicrobial agents and chemotherapy. 64(11) [DOI] 10.1128/AAC.01610-20. [PMID] 32900682.
Developing New Drugs for Mycobacterium tuberculosis Therapy: What Information Do We Get from Preclinical Animal Models?
Antimicrobial agents and chemotherapy. 64(12) [DOI] 10.1128/AAC.01376-20. [PMID] 32958720.
Examination of Metoprolol Pharmacokinetics and Pharmacodynamics Across CYP2D6 Genotype-Derived Activity Scores.
CPT: pharmacometrics & systems pharmacology. 9(12):678-685 [DOI] 10.1002/psp4.12563. [PMID] 33067866.
Machine Learning in Drug Discovery and Development Part 1: A Primer.
CPT: pharmacometrics & systems pharmacology. 9(3):129-142 [DOI] 10.1002/psp4.12491. [PMID] 31905263.
Open Data Revolution in Clinical Research: Opportunities and Challenges.
Clinical and translational science. 13(4):665-674 [DOI] 10.1111/cts.12756. [PMID] 32004409.
Pharmacokinetics of tedizolid, sutezolid, and sutezolid-M1 in non-human primates.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 151 [DOI] 10.1016/j.ejps.2020.105421. [PMID] 32531349.
Predicting Cost-Effectiveness of Generic vs. Brand Dabigatran Using Pharmacometric Estimates Among Patients with Atrial Fibrillation in the United States.
Clinical and translational science. 13(2):352-361 [DOI] 10.1111/cts.12719. [PMID] 32053288.
Quantitative Benefit-Risk Assessment of P-gp-Mediated Drug-Drug Interactions of Dabigatran Coadministered With Pharmacokinetic Enhancers in Patients With Renal Impairment.
Clinical pharmacology and therapeutics. [DOI] 10.1002/cpt.2087. [PMID] 33073366.
Using Physiologically Based Pharmacokinetic Modeling to Assess the Risks of Failing Bioequivalence Criteria: a Tale of Two Ibuprofen Products.
The AAPS journal. 22(5) [DOI] 10.1208/s12248-020-00495-4. [PMID] 32830289.
Evaluating the Clinical Impact of Formulation Variability: A Metoprolol Extended-Release Case Study.
Journal of clinical pharmacology. 59(9):1266-1274 [DOI] 10.1002/jcph.1433. [PMID] 31087554.
Pharmacometrics, Physiologically Based Pharmacokinetics, Quantitative Systems Pharmacology-What’s Next?-Joining Mechanistic and Epidemiological Approaches.
CPT: pharmacometrics & systems pharmacology. 8(6):352-355 [DOI] 10.1002/psp4.12425. [PMID] 31179639.
Towards regulatory endorsement of drug development tools to promote the application of model-informed drug development in Duchenne muscular dystrophy.
Journal of pharmacokinetics and pharmacodynamics. 46(5):441-455 [DOI] 10.1007/s10928-019-09642-7. [PMID] 31127458.
Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Molecules (Basel, Switzerland). 22(9) [DOI] 10.3390/molecules22091515. [PMID] 28891960.
A Biomechanical Model of Cortical Folding
Association for Women in Mathematics Series. 41-55 [DOI] 10.1007/978-3-319-16348-2_4.


Feb 2020 ACTIVE
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Designs for Type 1 Diabetes Prevention Studies
Role: Principal Investigator
Funding: JDRF
Jul 2019 ACTIVE
OoR Matching Support for CTSI
Role: Project Manager
Mar 2019 – Mar 2020
A Model-based Clinical Trial Simulation Tool to Optimize Clinical Trial Design of Studies to Investigate Efficacy of Potential Therapies for Duchenne Muscular Dystrophy
Role: Principal Investigator


2015 · Florida State University
2010 · Hanyang University
2008 · Hanyang University

Contact Details

(407) 313-7044